FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company with 275+ patents, will host an exclusive investor webinar on July 10, 2025, at 4:15 p.m. ET. CEO Pete O'Heeron will present the company's innovative fibroblast-based cell therapy platform targeting chronic, inflammatory, and degenerative conditions.
The presentation will highlight their lead candidate CYWC628 for diabetic foot ulcers, along with programs targeting degenerative disc disease and multiple sclerosis. FibroBiologics' approach uses allogeneic fibroblasts to develop scalable, off-the-shelf solutions, leveraging these cells' regenerative and immunomodulatory properties. The webinar will include a Q&A session, and a recording will be available on the company's website.
FibroBiologics (Nasdaq: FBLG), una società biotecnologica in fase clinica con oltre 275 brevetti, terrà un webinar esclusivo per investitori il 10 luglio 2025 alle 16:15 ET. Il CEO Pete O'Heeron presenterà la piattaforma innovativa di terapia cellulare a base di fibroblasti, mirata a condizioni croniche, infiammatorie e degenerative.
La presentazione metterà in evidenza il candidato principale CYWC628 per le ulcere del piede diabetico, insieme ai programmi dedicati alla malattia degenerativa del disco e alla sclerosi multipla. L'approccio di FibroBiologics utilizza fibroblasti allogenici per sviluppare soluzioni scalabili e pronte all'uso, sfruttando le proprietà rigenerative e immunomodulatorie di queste cellule. Il webinar includerà una sessione di domande e risposte e la registrazione sarà disponibile sul sito web dell'azienda.
FibroBiologics (Nasdaq: FBLG), una empresa biotecnológica en etapa clínica con más de 275 patentes, organizará un seminario web exclusivo para inversores el 10 de julio de 2025 a las 4:15 p.m. ET. El CEO Pete O'Heeron presentará la innovadora plataforma de terapia celular basada en fibroblastos dirigida a condiciones crónicas, inflamatorias y degenerativas.
La presentación destacará su candidato principal CYWC628 para úlceras del pie diabético, junto con programas enfocados en la enfermedad degenerativa del disco y la esclerosis múltiple. El enfoque de FibroBiologics utiliza fibroblastos alogénicos para desarrollar soluciones escalables y listas para usar, aprovechando las propiedades regenerativas e inmunomoduladoras de estas células. El seminario incluirá una sesión de preguntas y respuestas, y la grabación estará disponible en el sitio web de la empresa.
FibroBiologics (나스닥: FBLG)는 275개 이상의 특허를 보유한 임상 단계의 바이오테크 기업으로, 2025년 7월 10일 오후 4시 15분(동부시간)에 투자자 전용 웨비나를 개최합니다. CEO 피트 오히런이 만성, 염증성 및 퇴행성 질환을 타깃으로 하는 혁신적인 섬유아세포 기반 세포 치료 플랫폼을 소개할 예정입니다.
발표에서는 당뇨병성 족부 궤양 치료제인 CYWC628을 비롯해 퇴행성 추간판 질환과 다발성 경화증을 겨냥한 프로그램들을 강조할 것입니다. FibroBiologics의 접근법은 동종 섬유아세포를 활용해 확장 가능하고 즉시 사용 가능한 치료법을 개발하며, 이 세포들의 재생 및 면역조절 특성을 활용합니다. 웨비나에는 질의응답 세션이 포함되며, 녹화본은 회사 웹사이트에서 제공될 예정입니다.
FibroBiologics (Nasdaq : FBLG), une société biotechnologique en phase clinique avec plus de 275 brevets, organisera un webinaire exclusif pour investisseurs le 10 juillet 2025 à 16h15 ET. Le PDG Pete O'Heeron présentera la plateforme innovante de thérapie cellulaire à base de fibroblastes ciblant les affections chroniques, inflammatoires et dégénératives.
La présentation mettra en lumière leur principal candidat CYWC628 pour les ulcères du pied diabétique, ainsi que des programmes ciblant la maladie dégénérative des disques et la sclérose en plaques. L'approche de FibroBiologics utilise des fibroblastes allogéniques pour développer des solutions évolutives prêtes à l'emploi, tirant parti des propriétés régénératrices et immunomodulatrices de ces cellules. Le webinaire comprendra une session de questions-réponses, et un enregistrement sera disponible sur le site web de la société.
FibroBiologics (Nasdaq: FBLG), ein biotechnologisches Unternehmen in der klinischen Phase mit über 275 Patenten, wird am 10. Juli 2025 um 16:15 Uhr ET ein exklusives Investoren-Webinar veranstalten. CEO Pete O'Heeron wird die innovative, auf Fibroblasten basierende Zelltherapieplattform des Unternehmens vorstellen, die auf chronische, entzündliche und degenerative Erkrankungen abzielt.
Die Präsentation wird den führenden Kandidaten CYWC628 für diabetische Fußgeschwüre hervorheben sowie Programme, die sich auf degenerative Bandscheibenerkrankungen und Multiple Sklerose konzentrieren. Der Ansatz von FibroBiologics nutzt allogene Fibroblasten, um skalierbare, sofort verfügbare Lösungen zu entwickeln, wobei die regenerativen und immunmodulatorischen Eigenschaften dieser Zellen genutzt werden. Das Webinar beinhaltet eine Fragerunde, und eine Aufzeichnung wird auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, is pleased to invite investors to a webinar on July 10, 2025, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature FibroBiologics’ Founder and Chief Executive Officer, Pete O’Heeron, who will discuss FibroBiologics’ fibroblast-based cell therapy platform aimed at treating chronic, inflammatory, and degenerative conditions. Unlike traditional stem cell therapies, FibroBiologics’ allogeneic fibroblast approach can potentially deliver scalable, off-the-shelf solutions that harness the regenerative and immunomodulatory power of fibroblasts—cells that are abundant, immune-privileged, and cost-efficient to manufacture. Attendees will gain insight into FibroBiologics’ robust pipeline led by CYWC628 for diabetic foot ulcers and supported by additional candidates targeting multi-billion-dollar markets such as degenerative disc disease and multiple sclerosis, strong intellectual property portfolio, and anticipated upcoming clinical milestones.
A live question and answer session will follow the presentation. The recording of the presentation and Q&A will be available under the investor section of the FibroBiologics website after the event.
To register for the free webinar, please visit: https://www.redchip.com/webinar/FBLG/83262505545
Questions can be pre-submitted to FBLG@redchip.com or online during the live event.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the anticipated timing of the initiation of and results from, FibroBiologics’ current and future preclinical studies, clinical trials and research and development programs, potential clinical benefits of fibroblasts and fibroblast-derived materials, potential indications for FBLG’s programs, and estimates of market size. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When is FibroBiologics (FBLG) hosting its investor webinar in July 2025?
What therapeutic programs will FibroBiologics (FBLG) discuss during the webinar?
How many patents does FibroBiologics (FBLG) currently have?
How can investors access FibroBiologics' (FBLG) July 2025 webinar?
What is unique about FibroBiologics' (FBLG) therapeutic approach?
